(Q36341374)

13 August 2017

1 reference

title

Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients (English)

1 reference

13 August 2017

3

Johan Maertens

1 reference

13 August 2017

4

Georg Maschmeyer

1 reference

13 August 2017

Robert Betts

1

1 reference

13 August 2017

Axel Glasmacher

2

1 reference

13 August 2017

Jose A Vazquez

5

1 reference

13 August 2017

Hedy Teppler

6

1 reference

13 August 2017

Arlene Taylor

7

1 reference

13 August 2017

Robert Lupinacci

8

1 reference

13 August 2017

Carole Sable

9

1 reference

13 August 2017

Nicholas Kartsonis

10

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

13 August 2017

number of pages

8

1 reference

inferred from page(s)

published in

Cancer

1 reference

13 August 2017

volume

106

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

466-473

1 reference

Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

Opportunistic mycoses in the immunocompromised host: experience at a cancer center and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

A prospective study on fungal infection in children with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

Trends in the postmortem epidemiology of invasive fungal infections at a university hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Aspergillosis: The most common community-acquired pneumonia with gram-negative Bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Nosocomial pneumonia in patients having bone marrow transplant attributable mortality and risk factors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

The changing spectrum of candidemia in oncology patients: therapeutic implications

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Candidemia in cancer patients: a prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Predictors of adverse outcome in cancer patients with candidemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Predictors of outcome in cancer patients with candidemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

https://api.crossref.org/works/10.1002%2FCNCR.21615

1 reference

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Second-line therapy with caspofungin for mucosal or invasive candidiasis: results from the caspofungin compassionate-use study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Safety and tolerability of caspofungin acetate in the treatment of fungal infections

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

In vitro activities of semisynthetic pneumocandin L-733,560 against fluconazole-resistant and -susceptible Candida albicans isolates

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21615

7 January 2021

Identifiers

DOI

10.1002/CNCR.21615

1 reference

13 August 2017

1 reference